255 completed, 37 terminated, 10 recruiting, 10 withdrawn. 100 Phase 3, 75 Phase 2, 30 Phase 4, 28 Not applicable, 22 Phase 1.
Follow Ferring Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-09-17 |
| Embryo QUAlity in Ovarian Stimulation With hMG. 10 mcg of follitropin-delta + 150 of hMG, 5 mcg of follitropin-delta + 225 of hMG - Infertility | Phase 4 | Not yet recruiting | Fundacion Dexeus | 240 | 2026-09-01 | 2026-07-08 |
| Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauterine Successful Experience (RISE) REKOVELLE (Follitropin Delta) - Infertility, Insemination | Phase 2 | Recruiting | Centre Hospitalier Intercommunal Creteil | 80 | 2025-12-17 | 2026-04-08 |
| A Study to Measure Pharmacokinetic (PK) Concentrations of Gonadotropin-Releasing Hormone Delivered by the OmniPod Pump Lutrepulse - Amenorrhea, Fertility | Phase 1 | Withdrawn | Ferring Pharmaceuticals | 2025-09-12 | 2025-11-14 | |
| To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice Infertility | Active not recruiting | Ferring Pharmaceuticals | 2549 | 2025-08-05 | 2026-09-25 | |
| Menopur And Rekovelle Combination Study Version 2.0 Combination therapy : Follitropin delta and HP-hMG - IVF, Controlled Ovarian Simulation | Phase 2 | Recruiting | Clinique Ovo | 200 | 2025-07-04 | 2025-07-31 |
| Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis Nadofaragene Firadenovec - Low-grade Upper Tract Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Ferring Pharmaceuticals | 20 | 2025-06-12 | 2026-09-15 |
| Fast Track to Fertility Fast Track to Fertility Algorithmic Text Messaging Platform - Infertility | Not applicable | Completed | University of Pennsylvania | 162 | 2025-04-25 | 2026-10-02 |
| PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) Pre-eclampsia, Oocyte Donation | Recruiting | Copenhagen University Hospital, Hvidovre | 462 | 2024-10-21 | 2026-04-13 | |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer Nadofaragene Firadenovec, Gemcitabine, Docetaxel - Non-muscle Invasive Bladder Cancer With Carcinoma in Situ | Phase 3 | Recruiting | Ferring Pharmaceuticals | 250 | 2024-10-01 | 2026-09-25 |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer Nadofaragene Firadenovec - Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Recruiting | Ferring Pharmaceuticals | 454 | 2024-10-01 | 2026-10-21 |
| Ovulation Trigger Strategies in Low Ovarian Reserve (TRIGGERBEST) Human chorionic gonadotropin (hCG), Follitropin delta, Triptorelin - Low Ovarian Reserve, Poor Ovarian Response | Phase 3 | Recruiting | Fundación para la Investigación del Hospital Clínico de Valencia | 126 | 2024-09-17 | 2026-09-11 |
| Prospective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings REKOVELLE - Infertility | Active not recruiting | Ferring Pharmaceuticals | 1526 | 2024-08-27 | 2026-09-30 | |
| An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta at Different Time Intervals During Controlled Ovarian Stimulation. FE 999302, Follitropin delta, Placebo FE 999302 - Infertility | Phase 1 | Terminated | Ferring Pharmaceuticals | 106 | 2024-07-15 | 2026-03-30 |
| Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Japanese Persons FE 999301, Placebo - Gastroenterology | Phase 1 | Completed | Ferring Pharmaceuticals | 24 | 2024-07-01 | 2024-12-06 |
| A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. nadofaragene firadenovec - Bladder Cancer, Ta/T1 | Phase 4 | Withdrawn | Ferring Pharmaceuticals | 2024-06-17 | 2024-11-22 | |
| An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation Follitropin delta, FE999302, FE999302 Placebo - Fertility | Phase 1 | Terminated | Ferring Pharmaceuticals | 310 | 2024-06-14 | 2026-03-30 |
| A Randomised Trial Comparing the Ovarian Response of a Starting Dose of Either 10 μg or 15 μg Follitropin Delta (FE 999049) to a Starting Dose of Either 150 IU or 225 IU Follitropin Alfa (GONAL-F) in Conventional Regimens in China FE 999049, GONAL-F - Infertility, Female | Phase 3 | Completed | Ferring Pharmaceuticals | 301 | 2024-03-29 | 2026-02-12 |
| Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis Budesonide MMX®, Budesonide controlled ileal release (CR) capsules - Microscopic Colitis | Phase 2 | Active not recruiting | University of Calgary | 80 | 2024-03-21 | 2026-10-21 |
| A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis Microbiota suspension, Microbiota capsule, Placebo suspension - Ulcerative Colitis | Phase 1 | Withdrawn | Ferring Pharmaceuticals | 2024-03-12 | 2024-10-18 |
Showing 20 of 331. Sign in to see all of them.
Infertility (55) · Prostatic Neoplasms (54) · Colitis, Ulcerative (22) · Nocturia (20) · Crohn Disease (12) · Infertility, Female (12) · Inflammatory Bowel Diseases (6) · Dwarfism, Pituitary (5) · Menorrhagia (5) · Esophagitis, Peptic (4) · Eunuchism (4) · Nocturnal Enuresis (4) · Osteoarthritis, Knee (4) · Urinary Bladder Neoplasms (4) · Osteoarthritis (3)
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (57) · follitropin delta (21) · Deamino Arginine Vasopressin (19) · FE 999049 (13) · Menotropins (12) · Mesalamine (12) · follitropin alfa (12) · Progesterone (10) · Gonadotropin-Releasing Hormone (9) · picosulfate sodium (9) · Leuprolide (7) · Dinoprostone (6) · Goserelin (6) · Human Growth Hormone (6) · Tranexamic Acid (5)
United States (116) · Canada (52) · Germany (48) · Belgium (39) · Czechia (36) · France (35) · Denmark (33) · Spain (33) · United Kingdom (32) · Netherlands (28) · Poland (25) · Japan (24) · China (17) · Hungary (17) · Italy (16)
Daan Hommes, MD (3) · David Margel, MD, PhD (2) · Helen Colquhoun, MD (2) · Malcolm Boyce (2) · Malcolm J Boyce, FRCP FFPM (2) · Aimee Seungdamrong, MD (1) · Alvaro Morales, M.D. (1) · Andre-Guy Martin, MD MSc (1) · Andrew W Horne, Prof (1) · Angeline Beltsos, MD (1) · Anuja Dokras, MD, MHCI, PhD (1) · Arlen Jarrett, MD (1) · Arnold J. Weil, M.D. (1)
PMID 34350976, PMID 37156263, PMID 21043553, PMID 21367921, PMID 22607579, PMID 27862898, PMID 30801744, PMID 31397969, PMID 32364251, PMID 32819842, PMID 34254211, PMID 34799275, PMID 40714031, PMID 40728007, PMID 16980242, PMID 17077234, PMID 18281242, PMID 18474463, PMID 18538469, PMID 18801505, PMID 18827122, PMID 19035858, PMID 19125991, PMID 19622986, PMID 20139430, PMID 20859150, PMID 20942615, PMID 21225563, PMID 21343755, PMID 21737072, PMID 21777897, PMID 21788033, PMID 21820521, PMID 21867401, PMID 22197127, PMID 22244781, PMID 22447415, PMID 22500884, PMID 22961865, PMID 23257248, PMID 23258223, PMID 23394782, PMID 23451806, PMID 23454402, PMID 23454404, PMID 23548942, PMID 23618760, PMID 23677249, PMID 23811987, PMID 23857539
2008 (7), 2014 (4), 2015 (3), 2004 (2), 2009 (2), 2016 (2), 2017 (2), 2023 (2), 2025 (1)